Astria Therapeutics (ATXS)
(Delayed Data from NSDQ)
$7.52 USD
-0.17 (-2.21%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $7.53 +0.01 (0.13%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATXS 7.52 -0.17(-2.21%)
Will ATXS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ATXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATXS
All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy
Wall Street Analysts Believe Astria Therapeutics (ATXS) Could Rally 294.75%: Here's is How to Trade
ATXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Astria Therapeutics, Inc. (ATXS) Now Trades Above Golden Cross: Time to Buy?
Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect?
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year?
Other News for ATXS
ATXS forms 20 Day Moving Average Support on October 3
Is ATXS gathering momentum? Bollinger Band Squeeze shows up after advancing 1.99%
Astria Therapeutics (ATXS) Advances Phase 3 Trial for Hereditary Angioedema Treatment
Is ATXS showing upside potential? Crossed Above 20 Day Moving Average shows up after gaining 3.57%
Astria Therapeutics begins enrollment in EU for ALPHA-ORBIT trial